HJURP and breast cancer: Bravaccini et al. found that patients with in situ BC presenting high HJURP expression in the mesenchyme had a greater than 7-fold higher risk of recurrence, and suggested that HJURP could be used as a marker for the biological evolution of in situ BC (Bravaccini et al., 2014).